- Home
- VOR vs CATX Comparison
VOR vs CATX Comparison
Compare VOR & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- CATX
- Stock Information
- Founded
- VOR 2015
- CATX 1983
- Country
- VOR United States
- CATX United States
- Employees
- VOR N/A
- CATX N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- VOR Health Care
- CATX Health Care
- Exchange
- VOR Nasdaq
- CATX Nasdaq
- Market Cap
- VOR 207.1M
- CATX 239.0M
- IPO Year
- VOR 2021
- CATX N/A
- Fundamental
- Price
- VOR $29.40
- CATX $3.16
- Analyst Decision
- VOR Buy
- CATX Strong Buy
- Analyst Count
- VOR 6
- CATX 11
- Target Price
- VOR $85.33
- CATX $13.00
- AVG Volume (30 Days)
- VOR 526.1K
- CATX 1.1M
- Earning Date
- VOR 11-06-2025
- CATX 11-11-2025
- Dividend Yield
- VOR N/A
- CATX N/A
- EPS Growth
- VOR N/A
- CATX N/A
- EPS
- VOR N/A
- CATX N/A
- Revenue
- VOR N/A
- CATX $1,235,000.00
- Revenue This Year
- VOR N/A
- CATX N/A
- Revenue Next Year
- VOR N/A
- CATX N/A
- P/E Ratio
- VOR N/A
- CATX N/A
- Revenue Growth
- VOR N/A
- CATX N/A
- 52 Week Low
- VOR $2.62
- CATX $1.60
- 52 Week High
- VOR $65.80
- CATX $13.19
- Technical
- Relative Strength Index (RSI)
- VOR 52.41
- CATX 39.24
- Support Level
- VOR $28.65
- CATX $4.66
- Resistance Level
- VOR $31.31
- CATX $5.14
- Average True Range (ATR)
- VOR 3.26
- CATX 0.46
- MACD
- VOR -1.89
- CATX 0.00
- Stochastic Oscillator
- VOR 2.79
- CATX 9.64
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.